| Literature DB >> 24255593 |
Bullo Saifullah1, Mohd Zobir Hussein, Samer Hasan Hussein-Al-Ali, Palanisamy Arulselvan, Sharida Fakurazi.
Abstract
We report the intercalation and characterization ofEntities:
Keywords: biocompatible nanocomposites; drug-delivery system; slow-release nanocarrier; tuberculosis
Mesh:
Substances:
Year: 2013 PMID: 24255593 PMCID: PMC3832410 DOI: 10.2147/DDDT.S50665
Source DB: PubMed Journal: Drug Des Devel Ther ISSN: 1177-8881 Impact factor: 4.162
Figure 1X-ray diffraction patterns of PASA-D (A), PASA-I (B) and free PASA (C).
Abbreviations: PASA, para-amino salicylic acid; PASA-D, PASA nanocomposite prepared by direct method; PASA-I, PASA nanocomposite prepared by indirect method.
Figure 2Three-dimensional structure of PASA (A) and molecular structural models of PASA intercalated between interlayers of Zn/Al-LDH (B).
Abbreviations: PASA, para-amino salicylic acid; PASA-D, PASA nanocomposite prepared by direct method; PASA-I, PASA nanocomposite prepared by indirect method; Zn/Al-LDH, zinc/aluminum-layered double hydroxide.
Figure 3Fourier-transform infrared spectra of (A) PASA, (B) PASA-D, and (C) PASA-I.
Abbreviations: PASA, para-amino salicylic acid; PASA-D, PASA nanocomposite prepared by direct method; PASA-I, PASA nanocomposite prepared by indirect method.
Assignments of FTIR absorption bands of free PASA, PASA-D and PASA-I nanocomposites
| Assignments | Free PASA | PASA-D | PASA-I |
|---|---|---|---|
| ν (O–H) and ν (N–H) | 3,490, 3,381 | 3,343 in the layer; H2O | 3,340 |
| ν (COOH) | 1,609 | – | – |
| ν (C–C) | 1,519, 1,437 | 1,507, 1,451 | 1,505, 1,446 |
| δ (O–H) in plane | 1,283, 1,163 | 1,294, 1,157 | 1,292, 1,156 |
| δ (C–H) in plane | 1,109 | 1,090 | 1,090 |
| Ring-breathing mode | 962 | 972 | 1,012 |
| νas (COO−) | – | 1,564 | 1,560 |
| νs (COO−) | – | 1,361 | 1,355 |
Abbreviations: PASA, para-amino salicylic acid; PASA-D, PASA nanocomposite prepared by direct method; PASA-I, PASA nanocomposite prepared by indirect method; FTIR, fourier transform infrared spectroscopy.
Chemical compositions of PASA, PASA-D, and PASA-I nanocomposites
| Samples | Zn% | Al% | C% | N% | C/N | Drug% | Zn2+/Al3+ | X |
|---|---|---|---|---|---|---|---|---|
| PASA | – | – | 51.7 | 8.3 | 6.2 | – | – | – |
| PASA-D | 37.9 | 4.2 | 19.4 | 2.1 | 9.2 | 22.8 | 3.8 | 0.21 |
| PASA-I | 37.9 | 3.8 | 16.9 | 1.5 | 11.3 | 16.6 | 4.1 | 0.19 |
Notes:
Calculated from ICP data
calculated from CHNS data
calculated from UV data.
Abbreviations: PASA, para-amino salicylic acid; PASA-D, PASA nanocomposite prepared by direct method; PASA-I, PASA nanocomposite prepared by indirect method; UV, ultraviolet; CHNS, carbon, hydrogen, nitrogen, and sulfur; ICP, inductively coupled plasma; X, aluminium mole fraction.
Figure 4Thermogravimetric analysis–differential thermogravimetric thermograms of PASA (A), PASA-D (B), and PASA-I (C).
Abbreviations: PASA, para-amino salicylic acid; PASA-D, PASA nanocomposite prepared by direct method; PASA-I, PASA nanocomposite prepared by indirect method.
Figure 5Field-emission scanning electron micrographs of PASA-D (A and B) and PASA-I (C and D) nanocomposites at 50,000× and 100,000× magnifications.
Abbreviations: PASA, para-amino salicylic acid; PASA-D, PASA nanocomposite prepared by direct method; PASA-I, PASA nanocomposite prepared by indirect method.
Figure 6Release profiles of PASA from PASA-D (A) and PASA-I (B) nanocomposites into PBS at pH 7.4 and 4.8. Insets show the release profiles of PASA from nanocomposite at initial 500 minutes time.
Abbreviations: PASA, para-amino salicylic acid; PASA-D, PASA nanocomposite prepared by direct method; PASA-I, PASA nanocomposite prepared by indirect method.
Figure 7(A–D) Data fit of PASA release from PASA-D and PASA-I nanocomposites into pseudo-second-order kinetic model at pH 7.4 and 4.8.
Abbreviations: PASA, para-amino salicylic acid; PASA-D, PASA nanocomposite prepared by direct method; PASA-I, PASA nanocomposite prepared by indirect method.
Correlation coefficient (R2), and rate constants (k) obtained by fitting the data of PASA release from PASA-D and PASA-I nanocomposites into PBS solution at pH 4.8 and 7.4
| Samples | pH | Saturation release (%) | Pseudo-second-order
| |||
|---|---|---|---|---|---|---|
| Pseudo-first-order | Pseudo-second-order | Parabolic diffusion model | Rate constant | |||
| PASA-D | 7.4 | 88 | 0.8298 | 0.9946 | 0.8842 | 1.5 × 10−5 |
| PASA-D | 4.8 | 100 | 0.9129 | 0.9978 | 0.8369 | 3.3 × 10−5 |
| PASA-I | 7.4 | 57 | 0.9692 | 0.9952 | 0.9580 | 1.7 × 10−5 |
| PASA-I | 4.8 | 93 | 0.9103 | 0.9991 | 0.7849 | 5.2 × 10−5 |
Abbreviations: PASA, para-amino salicylic acid; PASA-D, PASA nanocomposite prepared by direct method; PASA-I, PASA nanocomposite prepared by indirect method; PBS, phosphate-buffered saline.
Figure 8Cell viability (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide [MTT] assay) of 3T3 mouse fibroblast cells and human lung fibroblast MRC-5 cells exposed to various gradient concentrations at 24, 48, and 72 hours’ exposure time. The data presented are means ± standard deviation of triplicate samples.
Abbreviations: PASA, para-amino salicylic acid; PASA-D, PASA by direct method; PASA-I, PASA by indirect method; ZLDH, zinc/aluminum-layered double hydroxide.